Compare Abeona Therapeutics Inc (ABEO) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs T Rowe Price Group Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while T Rowe Price Group Inc trades at $116.99 (market cap $24.27B). The key difference: T Rowe Price Group Inc is far larger — about 57.2× Abeona Therapeutics Inc's market cap, and T Rowe Price Group Inc pays a 4.57% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | TROW | |
|---|---|---|
Market Cap | $424.33M | $24.27B |
Sector | Health | Financials |
52-Week High | $7.45 | $121.68 |
52-Week Low | $4.17 | $86.19 |
Enterprise Value | $279.23M | $21.46B |
Dividend Yield | — | 4.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
T. Rowe Price (TROW) trades at $114.02, up 0.35% today, with a neutral technical outlook and mixed analyst sentiment. Recent Q2 2026 earnings beat expectations with EPS of $2.57 versus $2.51, driven by record assets under management and higher advisory fees. The stock trades at a P/E of 11.45, below industry averages, indicating potential undervaluation. Dividend payments remain stable at $1.30 per share, supporting income investors.
Outlook is cautiously optimistic given strong profitability metrics like a 29.26% net income margin and 20.1% ROE, but risks include expense pressures and net outflows. Analyst consensus price target is $112.17, slightly below current price, with 63% hold ratings suggesting limited near-term upside. Investors should weigh solid fundamentals against competitive headwinds in the asset management sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
